Physician profile
Shannon M Atkinson
NPI 1841369147
$62,841.91
in general payments reported to CMS, 2019-2025
41 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,621 · 2022: $8,729 · 2023: $3,336 · 2024: $22K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $11K · Travel and Lodging: $6,843 · Consulting Fee: $5,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,984.86 |
| Food and Beverage | $10,564.63 |
| Travel and Lodging | $6,843.07 |
| Consulting Fee | $5,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $36,790.05 | 2021-2025 | Tremfya, Stelara, Remicade |
| Janssen Scientific Affairs, LLC | $13,118.61 | 2021-2025 | Tremfya, Stelara |
| Abbvie INC. | $3,980.33 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,267.59 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,092.11 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $938.32 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $549.25 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $471.32 | 2021-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $420.74 | 2021-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $371.07 | 2021-2025 | |
| Ardelyx, INC. | $277.88 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $271.70 | 2024-2025 | Voquezna |
| Celgene Corporation | $259.73 | 2021-2023 | Zeposia |
| Genzyme Corporation | $219.29 | 2022-2024 | |
| Daiichi Sankyo INC. | $195.15 | 2021-2025 | Injectafer |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $182.94 | 2024-2025 | Omvoh |
| Novo Nordisk INC | $166.12 | 2025 | Wegovy |
| Medtronic, INC. | $162.30 | 2022-2024 | Endoflip |
| Organon LLC | $159.69 | 2022-2024 | Renflexis |
| Pfizer INC. | $145.24 | 2022-2025 | |
| Redhill Biopharma INC. | $120.33 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Ferring Pharmaceuticals INC. | $104.59 | 2021-2023 | Rebyota |
| Amgen INC. | $59.91 | 2022-2023 | Amjevita, Avsola |
| Alnylam Pharmaceuticals INC. | $50.94 | 2022-2025 | Givlaari |
| Merck Sharp & Dohme LLC | $48.77 | 2021-2022 | |
| Insulet Corporation | $45.01 | 2024 | Omnipod |
| Evoke Pharma, INC. | $43.55 | 2023-2025 | Gimoti |
| Dynavax Technologies Corporation | $37.03 | 2021-2022 | |
| Ucb, INC. | $36.31 | 2021 | |
| Alfasigma USA, INC. | $34.36 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $33.38 | 2025 | Iqirvo |
| Astrazeneca Pharmaceuticals Lp | $31.09 | 2023 | Andexxa |
| Madrigal Pharmaceuticals | $29.54 | 2024-2025 | Resmetirom, Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $22.69 | 2021 | |
| Albireo Pharma, INC. | $18.13 | 2024 | Bylvay |
| Celltrion USA INC. | $16.84 | 2025 | Vegzelma |
| Fresenius Kabi USA, LLC | $16.66 | 2023 | Idacio |
| Braintree Laboratories, INC. | $14.79 | 2021 | |
| Aimmune Therapeutics, INC. | $13.48 | 2025 | Zenpep |
| Alexion Pharmaceuticals, INC. | $13.29 | 2023 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.